[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cipla Limited - Company Snapshot & SWOT Analysis

June 2019 | 20 pages | ID: C5D7D7173F1EN
NAVADHI Market Research Pvt Ltd

US$ 200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated in 1935. Cipla Limited was founded by Dr. K.A. Hamied. Cipla is a therapy leader in India for anti-malarial with a market share of over 34%. CIPLA has 34 manufacturing facilities.

The Revenues of CIPLA increased from INR 104.39 bn to INR 155.77 bn during 2014-2018. The growth rate of the company for 2014-2018 is around 10.52%.

In the next five years, the company is estimated to grow at a CAGR of 7.50%. The revenue is expected to reach INR 223.63 billion by 2023.

Scope of the Cipla Limited - Company Snapshot & SWOT Analysis Report
  • This report provides detailed information about Cipla Limited including value chain analysis, financial performance, business strategy and SWOT analysis.
  • The report identifies the growth drivers and inhibitors for global pharmaceutical market.
  • This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY

Scope of the Cipla Limited - Company Snapshot & SWOT Analysis Report
Research Methodology

2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET

3. COMPANY PROFILE

3.1 CIPLA Limited
  3.1.1 Company Profile
  3.1.2 CIPLA Limited in Pharmaceutical Manufacturing Value Chain
  3.1.3 CIPLA Limited: Financial Performance
  3.1.4 CIPLA Limited: Business Strategy
    3.1.4.1 Product Level Business Strategy
    3.1.4.2 Service Level Business Strategy
  3.1.5 SWOT Analysis of CIPLA Limited
    Strengths
    Weaknesses
    Opportunities
    Threats
  3.1.6 Key Customers of CIPLA Limited

4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET

Orphan Drugs
Biologics and Biosimilars
Current Trends

1. INCREASING SEVERITY OF DRUG PRICE CONTROLS

2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS

3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS

4. INCREASING FOCUS ON CELL THERAPY

5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM

6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS

7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY

Notes
Company Information

LIST OF EXHIBITS

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Cipla Limited
Exhibit 3.2 Contact Information of Cipla Limited
Exhibit 3.3 Cipla Limited in Pharmaceutical Manufacturing Value Chain
Exhibit 3.4 Cipla Limited Revenue 2014-2018 (in INR billion)
Exhibit 3.5 Year-wise Cipla Limited Revenue Growth 2014-2018 (in %)
Exhibit 3.6 Estimated Cipla Ltd. Revenue (in INR bn)
Exhibit 3.7 Key Products of Cipla Limited
Exhibit 3.8 Key Services of Cipla Limited
Exhibit 3.9 SWOT Analysis of Cipla Limited


More Publications